Aureliant Global Accountants is preparing a complete advisory website with audit support, accounting, tax, ESG, digital transformation, AI advisory, regulatory compliance, client portal workflows, secure payments, and Foundation impact pages.

Aureliant Global Accountants is preparing a complete advisory website with audit support, accounting, tax, ESG, digital transformation, AI advisory, regulatory compliance, client portal workflows, secure payments, and Foundation impact pages.

Industries

Healthcare & Life Sciences

R&D, clinical trial economics, and M&A in pharma, biotech, medtech, and health delivery.

Focus areas

0 phases
integrated trial-to-commercial planning
0+
markets with pricing & access projects

Evidence at every therapy stage

From discovery burn rates to ex-US launches, healthcare finance is capital cycles plus regulation. We bring modelling that respects science timelines and market access realities.

Before work begins, we clarify the operating context, governance expectations, and commercial pressures behind the brief. That gives the engagement a clear purpose before technical analysis starts.

The result is a more complete advisory view: what matters now, where risk may surface next, and how recommendations can be implemented without creating unnecessary hand-offs or ambiguity.

Scope

Clarify the decision, deadline, stakeholders, and evidence standard before work begins.

Delivery

Combine partner judgement, technical review, and practical implementation planning in one workstream.

Follow-through

Convert findings into owners, actions, and next steps that leadership can track after the session.

Healthcare & Life Sciences

Aureliant’s healthcare and life sciences work spans R&D cost capitalisation, revenue milestones, and collaboration accounting for licensing deals. We connect clinical operations data to the revenue story the street expects to see, with transparent sensitivity tables.

For providers and payers, we assist with service line economics, public payment rule changes, and M&A in fragmented regional markets. ESG, patient safety, and data ethics are on the same agenda as margin - we help you report both without contradictions.

Programme lenses

01
R&D

Study economics

Budget to accrual alignment across CRO, sites, and supply.

  • Milestone revenue
  • Cost allocation
  • Impairment triggers
02
Commercial

Launch & access

Payer evidence, price architecture, and distribution economics.

Outcomes that matter in diligence

IPR&D
purchase price allocations
GMP
quality spend vs inventory
DSO
payer and pharmacy timing
In healthcare, the audit trail and the patient trail have to be reconcilable - we work both sides of that line carefully.
Life sciences partner
Aureliant
Sector team

Partner with industry specialists

Tell us your timeline, reporting cadence, and stakeholders - we will propose a right-sized team with clear deliverables.